OUTLOOK THERAPEUTICS INC

Stock Chart, Company Information, and Scan Results

$2.77(as of Aug 18, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

OUTLOOK THERAPEUTICS INC Company Information, Fundamentals, and Technical Indicators

Stock Price$2.77
Ticker SymbolOTLK
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees23
CountyUSA
Market Cap$100.3M

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

OUTLOOK THERAPEUTICS INC In Our Stock Scanner

As of Aug 19, 2025
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Low PE RatiosScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.